Tissue Repair Ltd

TRP

Tissue Repair Ltd. is a clinical stage bio pharmaceutical company, which develops advanced wound healing products targeting applications in the chronic wound and aesthetic procedure aftercare markets, with the potential for further development of related technologies. The company is headquartered in Sydney, New South Wales. The company went IPO on 2021-11-18. The firm's core focus is entering Phase 3 clinical trials in chronic wounds for its lead drug candidate TR987, with a secondary focus on commercializing TR Pro+ a post procedure topical gel to accelerate healing and improve skin quality following cosmetic and medical procedures. Its TR Pro+ product provides a range of benefits that assists damaged skin to heal and maintains skin hydration for a moist healing environment to encourage normal scar formation. The firm is also focused on commercializing its propriety Glucoprime active pharmaceutical ingredient (API) to treat a variety of wounds and skin conditions. Glucoprime is a β-glucan molecule, which is designed to assist skin healing and is delivered topically in a hydrogel formulation.